Immunology/Immunotherapy

免疫学/免疫治疗

• 批准号: 8231128
• 负责人: MICHAEL J. WEBER
• 金额: $ 2.87万
• 依托单位: UNIVERSITY OF VIRGINIA
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-02-01 至 2017-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8231128
• 关键词: Antibodies; Antigens; Basic Science; CD8B1 gene; Cancer Center Support Grant; Cancer Histology; Cell physiology; Cells; Clinical; Clinical Research; Clinical Trials; Collaborations; Development; Doctor of Philosophy; Eastern Cooperative Oncology Group; Enrollment; Extramural Activities; Foundations; Funding; Goals; Hematologic Neoplasms; Hematopoiesis; Immune response; Immune system; Immunologic Monitoring; Immunology; Immunotherapeutic agent; Immunotherapy; Instruction; Investigation; Knowledge; Laboratories; Laboratory Research; Malignant - descriptor; Malignant Neoplasms; Molecular; Multicenter Trials; National Cancer Institute; Patients; Publications; Regulation; Research; Research Personnel; Research Support; Science; Source; T cell response; Testing; Tumor Antigens; Tumor Immunity; Vaccines; Work; base; cancer immunotherapy; cancer therapy; cytokine; improved; medical schools; member; programs; tool; tumor

The immune system is both a source of malignancies and a tool for cancer therapy. The Immunology/lmmunotherapy Program (IMM) supports basic and clinical research to increase the understanding and control of (1) the immune response to cancer and (2) the ways hematopoiefic cell development and its dysregulation can be used to treat hematologic malignancies. IMM Program members approach this two-faceted goal through three scientific Themes: (1) Development and Opfimizafion of Antigen-Directed Immunotherapeutics; (2) Positive and Negative Regulation of the Quality of Anti-Tumor Immunity. (3) Control of Hematopoiesis and Hematologic Malignancies. These Themes include outstanding basic science investigations, as well as highly collaborative translational initiatives to develop clinical trials based on this research. Program Co-Leader, Victor Engelhard, PhD, is internationally recognized for his work in tumor antigen identificafion and inducfion of tumor-specific CD8 T cell responses. Program Co-leader, Craig Slingluff, MD, has made major contribufions to cancer immunotherapy through both laboratory research and investigator-inifiated clinical trials. The Program consists of 27 Full Members and 3 Associate Members from six departments in the School of Medicine. Total extramural funding for the Program exceeds $17 million, including $4 million from the National Cancer Institute (NCI). Program Members have produced 293 cancer-relevant publications, of which 21% were inter-programmatic and 19% were intra-programmafic since the last renewal. The Program supports research in progress presentations and seminars to engender new direcfions and collaborafions; Pilot funding to encourage development of promising collaborations and ideas; and an Immune Monitoring Laboratory to facilitate clinical research. Seventeen investigator-initiated clinical trials led by Program Members, including hwo ECOG trials and three additional multicenter trials, have enrolled patients across six cancer histologies and evaluated pepfide vaccines, cytokines, and antibodies. These trials test hypotheses arising from laboratory science and also bring fissue to the laboratories to invesfigate cellular processes and molecular mechanisms to explain the clinical findings. This Program provides a firm foundation for confinued advances in both understanding of the immune system and ufilizing that knowledge to improve immunotherapy and treatment of hematologic malignancies.

免疫系统既是恶性肿瘤的根源，也是癌症治疗的工具。这 免疫学/免疫治疗计划 (IMM) 支持基础和临床研究，以提高 了解和控制 (1) 对癌症的免疫反应和 (2) 造血细胞的方式 发育及其失调可用于治疗血液恶性肿瘤。 IMM 计划成员 通过三个科学主题来实现这个两个方面的目标：（1）开发和优化 抗原定向免疫治疗； (2)抗肿瘤质量的正向和负向调节 免疫。 (3) 控制造血和血液恶性肿瘤。这些主题包括杰出的 基础科学研究以及开发临床试验的高度协作转化计划 基于这项研究。项目联合负责人 Victor Engelhard 博士因其工作而获得国际认可 肿瘤抗原识别和肿瘤特异性 CD8 T 细胞反应的诱导。项目联合负责人， Craig Slingluff 医学博士通过两项实验室研究为癌症免疫治疗做出了重大贡献 和研究者发起的临床试验。该计划由 27 名正式会员和 3 名准会员组成 来自医学院的六个系。该计划的外部资金总额超过 17 美元 百万美元，其中包括美国国家癌症研究所 (NCI) 提供的 400 万美元。计划成员已制作了 293 癌症相关出版物，其中 21% 是计划间出版物，19% 是计划内出版物 最后一次更新。该计划支持进展中的研究演示和研讨会，以产生新的 指导和合作；试点资助，鼓励发展有前途的合作和想法； 和免疫监测实验室以促进临床研究。十七名研究者发起的临床 由计划成员领导的试验，包括 hwo ECOG 试验和另外三项多中心试验， 招募了六种癌症组织学的患者，并评估了肽疫苗、细胞因子和抗体。 这些试验检验了实验室科学提出的假设，并将组织带到实验室 研究细胞过程和分子机制以解释临床发现。本计划 为理解免疫系统和利用免疫系统的持续进步提供了坚实的基础 这些知识可以改善免疫疗法和血液恶性肿瘤的治疗。